This “MTORC1 Protein Inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in MTORC1 Protein Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
m TOR is a serine/threonine protein kinase in the PI3K-related kinase (PIKK) family that forms the catalytic subunit of two distinct protein complexes, known as m TOR Complex 1 (mTORC1) and 2 (mTORC2). mTORC1 is defined by its three core components: mTOR, Raptor (regulatory protein associated with mTOR), and mLST8 (mammalian lethal with Sec13 protein 8, also knownasGßL).
Function - In order to grow and divide, cells must increase production of proteins, lipids, and nucleotides while also suppressing catabolic pathways such as autophagy. m TORC1 plays a central role in regulating all of these processes, and therefore controls the balance between anabolism and catabolism in response to environmental conditions. m TORC1 promotes protein synthesis largely through the phosphorylation of two key effectors, p70S6 Kinase 1 (S6K1) and eIF4E Binding Protein (4EBP). mTORC1 directly phosphorylates S6K1 on its hydrophobic motif site, Thr389, enabling its subsequent phosphorylation and activationbyPDK1.
MTORC1 Protein Inhibitors - New m TOR-specific inhibitors came forth from screening and drug discovery efforts. These compounds block activity of both m TOR complexes and are called mTORC1/mTORC2 dual inhibitors. Compounds with this characteristics such as sapanisertib have entered clinical trials. A series of these mTOR kinase inhibitors have been studied. Their structure is derived from morpholino pyrazolopyrimidine scaffold. Improvements of this type of inhibitors have been made by exchanging the morpholines with bridged morpholines in pyrazolopyrimidine inhibitors and results showed increased selectivity to mTOR by26000fold.
This product will be delivered within 2 business days.
Geography Covered
- Global coverage
MTORC1 Protein Inhibitors Understanding
Overviewm TOR is a serine/threonine protein kinase in the PI3K-related kinase (PIKK) family that forms the catalytic subunit of two distinct protein complexes, known as m TOR Complex 1 (mTORC1) and 2 (mTORC2). mTORC1 is defined by its three core components: mTOR, Raptor (regulatory protein associated with mTOR), and mLST8 (mammalian lethal with Sec13 protein 8, also knownasGßL).
Function - In order to grow and divide, cells must increase production of proteins, lipids, and nucleotides while also suppressing catabolic pathways such as autophagy. m TORC1 plays a central role in regulating all of these processes, and therefore controls the balance between anabolism and catabolism in response to environmental conditions. m TORC1 promotes protein synthesis largely through the phosphorylation of two key effectors, p70S6 Kinase 1 (S6K1) and eIF4E Binding Protein (4EBP). mTORC1 directly phosphorylates S6K1 on its hydrophobic motif site, Thr389, enabling its subsequent phosphorylation and activationbyPDK1.
MTORC1 Protein Inhibitors - New m TOR-specific inhibitors came forth from screening and drug discovery efforts. These compounds block activity of both m TOR complexes and are called mTORC1/mTORC2 dual inhibitors. Compounds with this characteristics such as sapanisertib have entered clinical trials. A series of these mTOR kinase inhibitors have been studied. Their structure is derived from morpholino pyrazolopyrimidine scaffold. Improvements of this type of inhibitors have been made by exchanging the morpholines with bridged morpholines in pyrazolopyrimidine inhibitors and results showed increased selectivity to mTOR by26000fold.
MTORC1 Protein Inhibitors Emerging Drugs Chapters
This segment of the MTORC1 Protein Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.MTORC1 Protein Inhibitors Emerging Drugs
Onatasertib (CC 223): Celgene CC-223 is an orally available inhibitor of the mammalian target of rapamycin (m TOR) with potential antineoplastic activity. mTOR kinase inhibitor CC-223 inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. CC-223 disrupted mitochondrial function, and induced mitochondrial permeability transition pore (mPTP) opening and reactive oxygen species (ROS) production. CC-223 is currently in phase II clinical trials for the treatment of Liver cancer; Non-small cell lung cancer; andSolidtumours.- Sapanisertib :Takeda Oncology
MTORC1 Protein Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different MTORC1 Protein Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:Major Players working on MTORC1 Protein Inhibitors
There are approx. 5+ key companies which are developing the MTORC1 Protein Inhibitors. The companies which have their MTORC1 Protein Inhibitors drug candidates in the most advanced stage, i.e. phase II include, Celgene.Phases
This report covers around 5+ products under different phases of clinical development like- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
MTORC1 Protein Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
Molecule Type
Products have been categorized under various Molecule types such as
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.MTORC1 Protein Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses MTORC1 Protein Inhibitors therapeutic drugs key players involved in developing key drugs.Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging MTORC1 Protein Inhibitors drugs.Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence MTORC1 Protein Inhibitors R&D. The therapies under development are focused on novel approaches for MTORC1 Protein Inhibitors.MTORC1 Protein Inhibitors Report Insights
- MTORC1 Protein Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
MTORC1 Protein Inhibitors Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Scenario and Emerging Therapies:- How many companies are developing MTORC1 Protein Inhibitors drugs?
- How many MTORC1 Protein Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for MTORC1 Protein Inhibitors?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the MTORC1 Protein Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for MTORC1 Protein Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Celgene
- Takeda Oncology
- Mount Tam Biotechnologies
- Cerecor
- Adicet Bio
- Aeonian Pharmaceuticals
- Boehringer Ingelheim
- REVOLUTION Medicines
Key Products
- Sotorasib
- Sapanisertib
- m TORC1 inhibitor programmeII
- XP 105
- RMC-5552
This product will be delivered within 2 business days.
Table of Contents
IntroductionExecutive SummaryMTORC1 Protein Inhibitors - Analytical PerspectiveDrug profiles in the detailed report…..Drug profiles in the detailed report…..Drug profiles in the detailed report…..Drug profiles in the detailed report…..MTORC1 Protein Inhibitors Key CompaniesMTORC1 Protein Inhibitors Key ProductsMTORC1 Protein Inhibitors- Unmet NeedsMTORC1 Protein Inhibitors- Market Drivers and BarriersMTORC1 Protein Inhibitors- Future Perspectives and ConclusionMTORC1 Protein Inhibitors Analyst ViewsMTORC1 Protein Inhibitors Key CompaniesAppendix
MTORC1 Protein Inhibitors: Overview
Pipeline Therapeutics
Therapeutic Assessment
In-depth Commercial Assessment
MTORC1 Protein Inhibitors Collaboration Deals
Late Stage Products (Pre-registration)
Drug name: Company name
Mid Stage Products (Phase II)
Onatasertib (CC 223): Celgene
Early Stage Products (Phase I)
CERC 006: Cerecor
Pre-clinical and Discovery Stage Products
Research programme: mTOR inhibitors: Mount Tam Biotechnologies
Inactive Products
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Celgene
- Takeda Oncology
- Mount Tam Biotechnologies
- Cerecor
- Adicet Bio
- Aeonian Pharmaceuticals
- Boehringer Ingelheim
- REVOLUTION Medicines
